Back to results
US 8,802,113 B2Granted
Extracellular matrix cancer vaccine adjuvant
AssigneeUniversity of Notre Dame
InventorsWilliam R. Wolter, Mark S. Suckow
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Notre Dame
InventorsWilliam R. Wolter, Mark S. Suckow
Estimating the term…
Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.
A pharmaceutical preparation comprising a tumor-cell conditioned extracellular matrix material and replication incompetent tumor cells, wherein the extracellular matrix material is from a non-tumor tissue source.
An implantable preparation comprising a tumor-cell conditioned extracellular matrix material, and tumor tissue cells comprising replication incompetent tumor cells, wherein extracellular matrix material is from a non-tumor tissue source.
A pharmaceutical preparation comprising a prostate tumor cell conditioned extracellular matrix material, and replication incompetent prostate tumor cells, wherein extracellular matrix material is from a non-tumor tissue source.
Dependencies are inferred from the claim text.